Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04765098 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 2026 to Dec 2026
    • Study completion date: Dec 2026 to Jul 2027
    v6
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2021 to Jan 28, 2022
    • Site details revised
    v4
  4. Start date: Jun 2021 to Aug 2021v3 Show 6 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Jun 2026 to Aug 2026
    • Interventions: Lomustine (Drug), Tamoxifen (Drug) to Etoposide (Drug), Tamoxifen (Drug)
    • Eligibility criteria expanded, about 93 words
    • Secondary endpoints: 3 to 4
    • Study title revised
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AHS Cancer Control Alberta
42 trials monitored
See 2 trials at risk
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
Trial Details
NCT Number NCT04765098
Lead Sponsor AHS Cancer Control Alberta
Conditions
(from sponsor)		 Glioblastoma Multiforme
Related terms Glioblastoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov